Imidazoquinoline Analgesics Modulating COX-2 Transcription
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and pain-related disorders, such as arthritis and cancer, face challenges due to the adverse effects of COX-2 inhibitors and the inefficacy of existing analgesics in managing neuropathic pain, along with the complexity of cytokine and COX-2 regulation in inflammatory diseases.
Innovation Solution
Development of novel 6-1H-imidazo-2-aryl and 2-heteroaryl quinazoline and quinoline compounds that interfere with COX-2 and cytokine production, offering a new class of pharmacological agents for treating inflammatory and neuropathic pain without inhibiting cyclooxygenase enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX-2 inhibitors are used to treat inflammatory diseases and pain, then anti-inflammatory and analgesic effects are improved, but gastrointestinal toxicity and cardiovascular adverse effects worsen
Solution Approach 1:
The patent extracts the transcriptional regulation mechanism of COX-2 from the enzyme itself, targeting the gene expression level rather than the enzymatic activity. This separates the therapeutic effect (reducing COX-2 expression) from the harmful effects associated with enzyme inhibition, thereby maintaining efficacy while reducing toxicity
Solution Approach 2:
The patent introduces transcriptional regulation as an intermediary mechanism between the drug and COX-2 enzyme activity. By targeting gene expression through transcriptional factors and signaling pathways (such as NF-κB, AP-1, and STAT), the drug indirectly reduces COX-2 levels without directly inhibiting the enzyme, thus avoiding the toxicities associated with direct enzyme inhibition
2Reliability
If classical NSAIDs are used to treat inflammatory diseases, then anti-inflammatory effects are improved, but gastrointestinal side effects worsen
Solution Approach 1:
The patent extracts the therapeutic effect from the direct enzyme inhibition mechanism and relocates it to the transcriptional regulation level. By targeting COX-2 gene expression rather than enzymatic activity, the patent eliminates the gastrointestinal toxicity mechanism while preserving the anti-inflammatory benefit
Solution Approach 2:
Instead of inhibiting the enzyme activity (the conventional approach), the patent inverts the strategy by promoting or suppressing the gene expression level. This inversion allows control of COX-2 levels at the source (transcription) rather than at the functional level (enzyme activity), thereby avoiding off-target effects on gastrointestinal prostaglandins
3Reliability
If corticosteroids are used to treat inflammatory diseases, then anti-inflammatory effects are improved, but severe side effects worsen
Solution Approach 1:
The patent applies local quality by targeting specific transcriptional pathways (such as NF-κB, AP-1, STAT) that are selectively involved in COX-2 regulation in inflammatory tissues. This selective transcriptional modulation provides localized anti-inflammatory action without the systemic side effects of corticosteroids
Solution Approach 2:
The patent changes the therapeutic parameter from broad-spectrum anti-inflammatory action (corticosteroids) to specific transcriptional pathway modulation. By targeting the molecular switches (transcriptional factors) that control COX-2 expression, the patent achieves inflammation-specific control with a more favorable safety profile
4Reliability
If existing analgesics are used to manage pain, then analgesic effects are improved, but efficacy in neuropathic pain worsens
Solution Approach 1:
The patent confers universality by designing a compound that can address multiple pain mechanisms through a single transcriptional regulation target. By modulating COX-2 expression at the gene level, the compound can effectively treat both inflammatory pain (through reduced prostaglandin production) and neuropathic pain (through anti-nociceptive effects), overcoming the limitations of type-specific analgesics
Data Source
AI summary
The present invention is directed to novel 6-lH-imidazo-2- aryl and 2-heteroaryl quinazoline and quinoline of Formula (I), corresponding salts and solvates thereof, to a process for their preparation and to the use of this compounds and corresponding pharmaceutical composition for the treatment of pain and inflammatory related disorders. Compounds of the invention have been proven highly effective in the pharmacological treatment of both inflammatory and neuropathic pain, in addition to striking anti-inflammatory properties. Their effectiveness in interfering with COX-2 and inflammatory cytokines expressions and production, highlights them as interesting compounds also for the treatment of cancer in addition to several inflammatory diseases.